In summary, this study found that cervical prescription mainly uses TGFβ1, PPP6C, HIF1A, IL1B, and other gene targets through network pharmacology and regulates cancer pathways, FoxO signaling pathway, IL-17, and other signaling pathways to regulate immunity and improve cervical cell pathology in patients with cervical cancer, thereby exerting therapeutic effects of cervical cancer. The gene discussed is HIF1A; the disease is cervical cancer.